ArticleJournal of gastrointestinal oncology2026
A TRPM4-associated necrotic cell death signature for prognostic stratification in pancreatic cancer.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sodium overload-induced necrotic cell death has been proposed as a stress-related cellular process potentially involved in tumor progression, but its relevance in pancreatic cancer remains poorly understood. TRPM4, a sodium-permeable ion channel, has been implicated in cellular stress responses; however, the prognostic significance of TRPM4 and its associated transcriptional features in pancreatic cancer has not been comprehensively evaluated. This study integrated multi-cohort transcriptomic datasets to construct a prognostic risk score model based on TRPM4-associated genes. Methods: Genes co-expressed with TRPM4 were identified in The Cancer Genome Atlas-pancreatic adenocarcinoma (TCGA-PAAD) cohort. Survival-associated genes were screened using univariate Cox regression and further refined by least absolute shrinkage and selection operator (LASSO) Cox regression to construct a TRPM4-associated prognostic risk score. An independent Gene Expression Omnibus (GEO) dataset was used for external validation. Kaplan-Meier survival analysis, multivariate Cox regression, and time-dependent receiver operating characteristic (ROC) analyses were applied. Exploratory analyses of somatic mutation patterns inferred immune infiltration, and drug sensitivity-related transcriptional features were also performed. Results: We identified 60 TRPM4-associated genes, among which seven (MSLN, RAB27B, MYEOV, ECT2, KATNAL2, SAT2, and SLC26A11) constituted a related prognostic signature. Higher risk scores were significantly associated with worse prognosis, and correlation analysis further revealed supportive evidences between this high-risk score and poor clinicopathologic features, higher somatic mutations, more immune cell infiltration, and less clinical drug sensitivity. Conclusions: This study identifies a TRPM4-associated prognostic signature that enables risk stratification in pancreatic cancer. While based on retrospective transcriptomic analyses, the proposed model provides a framework for prognostic evaluation and warrants further prospective and experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.